KIZUNA
LIVE

Serial Number

98785571

Owner

Flagship Labs 94, Inc.

Attorney

Christina M. Licursi

Filing Date

Oct 4, 2024

Add to watchlist:

No watchlists yet
View on USPTO

KIZUNA Trademark

Serial Number: 98785571

KIZUNA is a trademark filed by Flagship Labs 94, Inc. on October 4, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Flagship Labs 94, Inc. (3 trademarks)

55 Cambridge Parkway, Suite 800E
Cambridge, MA 02142

Entity Type: 03

EXPEDITION MEDICINES, INC. (7 trademarks)

55 CAMBRIDGE PARKWAY, SUITE 800E
CAMBRIDGE, MA 02142

Entity Type: 03

Trademark Details

Filing Date

October 4, 2024

Registration Date

Not Registered

Goods & Services

Pharmaceuticals for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders; therapeutics, namely, therapeutic agents for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders; protein-based and small molecule therapeutics, namely, therapeutic agents for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders; protein-based and small molecule pharmaceuticals for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders

Downloadable software for use in the pharmaceuticals and healthcare fields, namely, for enabling and facilitating molecular research, research and development of pharmaceutical products and chemical compounds, design of chemical structures, and analysis of biological or chemical activity; downloadable software for providing life science analytics

Software as a service (SAAS) services featuring software using artificial intelligence for use in the fields of healthcare for enabling and facilitating molecular research, research and development of pharmaceutical products and chemical compounds, design of chemical structures, and analysis of biological or chemical activity; software as a service (SAAS) services featuring software using artificial intelligence for use in the biotechnology field for discovering and designing biomolecules and chemical structures; software as a service (SAAS) services featuring software using artificial intelligence, computational methods, and machine learning models for data analysis in the fields of biomedical and genomic research; providing temporary use of on-line non-downloadable software featuring artificial intelligence, computational methods, and machine learning models for the design and characterization of biologic therapeutic products and drug analysis in drug discovery and development; scientific research, namely, research and analysis services for the design and characterization of chemical and biologic therapeutic products; research services in the fields of genomic, transcriptomic, and proteomic analysis; genomic and proteomic analysis and sequencing services for scientific and research purposes; medical and scientific research in the fields of genetics, genomics, proteomics, transcriptomics, epigenomics, metabolomics, meta-genomics, meta-transcriptomics, and microbiomics; DNA analysis and sequencing services for scientific and research purposes; research, development and consultancy in the field of genomics and proteomics; medical research, namely, compiling data for research purposes in the field of genomics and proteomics; providing on-line non-downloadable software for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, proteomics, transcriptomics, epigenomics, metabolomics, meta-genomics, meta-transcriptomics, and microbiomics; platform as a service (PaaS) featuring computer software platforms for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, proteomics, transcriptomics, epigenomics, metabolomics, meta-genomics, meta-transcriptomics, and microbiomics; software as a service (SAAS) services featuring software for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, proteomics, transcriptomics, epigenomics, metabolomics, meta-genomics, and meta-transcriptomics

Filing History

REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
May 7, 2026 RCSC
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Nov 3, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Nov 3, 2025 GNSL
SUSPENSION LETTER WRITTEN
Nov 3, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 22, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 22, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 22, 2025 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jul 1, 2025 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jul 1, 2025 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 22, 2025 GNRN
NON-FINAL ACTION E-MAILED
Apr 22, 2025 GNRT
NON-FINAL ACTION WRITTEN
Apr 22, 2025 CNRT
ASSIGNED TO EXAMINER
Apr 9, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 3, 2025 NWOS
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Mar 5, 2025 ASGN
NEW APPLICATION ENTERED
Oct 4, 2024 NWAP